000290536 001__ 290536
000290536 005__ 20241219141011.0
000290536 0247_ $$2doi$$a10.1007/s00117-024-01312-1
000290536 0247_ $$2pmid$$apmid:38743100
000290536 0247_ $$2ISSN$$a2731-7048
000290536 0247_ $$2ISSN$$a0033-832X
000290536 0247_ $$2ISSN$$a1432-2102
000290536 0247_ $$2ISSN$$a2731-7056
000290536 037__ $$aDKFZ-2024-01153
000290536 041__ $$aGerman
000290536 082__ $$a610
000290536 1001_ $$0P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4$$ade Vrieze, Maxime$$b0$$eFirst author$$udkfz
000290536 245__ $$aProstate cancer screening - current overview.[Das Prostatakarzinom-Screening – aktueller Überblick].
000290536 260__ $$a[Berlin]$$bSpringer Medizin Verlag GmbH$$c2024
000290536 3367_ $$2DRIVER$$aarticle
000290536 3367_ $$2DataCite$$aOutput Types/Journal article
000290536 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719820503_5814$$xReview Article
000290536 3367_ $$2BibTeX$$aARTICLE
000290536 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290536 3367_ $$00$$2EndNote$$aJournal Article
000290536 500__ $$a#EA:C130#
000290536 520__ $$aThe harm-to-benefit ratio of prostate cancer (PCa) screening remains controversial mainly due to the unfavorable test characteristics of prostate-specific antigen (PSA) as a screening test.In this nonsystematic review, we present a current overview of the body of evidence on prostate cancer screening with a focus on the role of magnetic resonance imaging (MRI) of the prostate.Evidence generated in large randomized controlled trials showed that PSA-based screening significantly decreases cancer-specific mortality. The main obstacle in developing and implementing PCa screening strategies is the resulting overdiagnosis and as a consequence overtreatment of indolent cancers. Opportunistic screening is characterized by an adverse benefit-to-harm ratio and should, therefore, not be recommended. The German Statutory Early Detection Program for prostate cancer, which consists of a digital rectal examination (DRE) as a stand-alone screening test, is not evidence-based, neither specific nor sensitive enough and results in unnecessary diagnostics. The European Commission recently urged member states to develop population-based and organized risk-adapted PSA-based screening programs, which are currently tested in the ongoing German PROBASE trial. Finetuning of the diagnostic pathway following PSA-testing seems key to improve its positive and negative predictive value and thereby making PCa screening more accurate. Incorporation of prostatic MRI into screening strategies leads to more accurate diagnosis of clinically significant prostate cancer, while diagnosis of indolent cancers is reduced. In the future, molecular liquid-based biomarkers have the potential to complement or even replace PSA in PCa screening and further personalize screening strategies. Active surveillance as an alternative to immediate radical therapy of demographically increasing PCa diagnoses can potentially further improve the benefit-to-harm ratio of organized screening.Early detection of PCa should be organized on a population level into personalized and evidence-based screening strategies. Multiparametric MRI of the prostate may play a key role in this setting.
000290536 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000290536 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290536 650_7 $$2Other$$aCancer-specific mortality
000290536 650_7 $$2Other$$aMagnetic resonance imaging
000290536 650_7 $$2Other$$aProstate neoplasms
000290536 650_7 $$2Other$$aProstate-specific antigen
000290536 650_7 $$2Other$$aScreening strategy
000290536 650_7 $$0EC 3.4.21.77$$2NLM Chemicals$$aProstate-Specific Antigen
000290536 650_2 $$2MeSH$$aHumans
000290536 650_2 $$2MeSH$$aProstatic Neoplasms: diagnosis
000290536 650_2 $$2MeSH$$aProstatic Neoplasms: diagnostic imaging
000290536 650_2 $$2MeSH$$aProstatic Neoplasms: blood
000290536 650_2 $$2MeSH$$aMale
000290536 650_2 $$2MeSH$$aEarly Detection of Cancer: methods
000290536 650_2 $$2MeSH$$aMagnetic Resonance Imaging: methods
000290536 650_2 $$2MeSH$$aProstate-Specific Antigen: blood
000290536 650_2 $$2MeSH$$aMass Screening: methods
000290536 650_2 $$2MeSH$$aGermany
000290536 650_2 $$2MeSH$$aAged
000290536 7001_ $$aHübner, Anne$$b1
000290536 7001_ $$0P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811$$aAl-Monajjed, Rouvier$$b2$$udkfz
000290536 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b3$$udkfz
000290536 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b4$$udkfz
000290536 7001_ $$aSchimmöller, Lars$$b5
000290536 7001_ $$aBoschheidgen, Matthias$$b6
000290536 773__ $$0PERI:(DE-600)3120921-X$$a10.1007/s00117-024-01312-1$$gVol. 64, no. 6$$n6$$p479–487$$tDie Radiologie$$v64$$x2731-7048$$y2024
000290536 8564_ $$uhttps://inrepo02.dkfz.de/record/290536/files/s00117-024-01312-1.pdf
000290536 8564_ $$uhttps://inrepo02.dkfz.de/record/290536/files/s00117-024-01312-1.pdf?subformat=pdfa$$xpdfa
000290536 909CO $$ooai:inrepo02.dkfz.de:290536$$pVDB
000290536 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000290536 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000290536 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000290536 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000290536 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000290536 9141_ $$y2024
000290536 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-27$$wger
000290536 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-27$$wger
000290536 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000290536 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000290536 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000290536 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-27
000290536 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000290536 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-27
000290536 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-27
000290536 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOLOGIE : 2022$$d2023-10-27
000290536 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-27
000290536 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000290536 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x1
000290536 9200_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000290536 980__ $$ajournal
000290536 980__ $$aVDB
000290536 980__ $$aI:(DE-He78)C130-20160331
000290536 980__ $$aI:(DE-He78)E010-20160331
000290536 980__ $$aUNRESTRICTED